MV analysis for GvHD after non-MSD HCT
| Variable and categories . | N (N Event)* . | HR estimate (95% CI)† . | P . | Overall P‡ . |
|---|---|---|---|---|
| aGvHD2-4 | ||||
| Conditioning | ||||
| No/IS (baseline) | 343 (75) | 1.00 | .047 | |
| RIC/MAC | 202 (60) | 1.43 (1.01-2.03) | .047 | |
| Maternal T-cell result | ||||
| Searched for and absent (baseline) | 147 (37) | 1.00 | .004 | |
| ND | 311 (63) | 0.80 (0.52-1.22) | .303 | |
| Present | 87 (35) | 1.61 (0.99-2.61) | .053 | |
| Stratum | ||||
| A (baseline) | 481 (122) | 1.00 | .315 | |
| B | 64 (13) | 0.73 (0.40-1.35) | .315 | |
| cGvHD | ||||
| Donor type/TCD | ||||
| MMRD-TCD/soybean lectin (baseline) | 276 (35) | 1.00 | .019 | |
| MMRD-TCD/CD34 selection | 74 (12) | 1.16 (0.59-2.30) | .667 | |
| MMRD-other§ | 41 (10) | 3.00 (1.48-6.11) | .002 | |
| MORD | 25 (5) | 1.76 (0.69-4.52) | .239 | |
| URD | 116 (25) | 1.87 (1.10-3.18) | .021 | |
| Maternal T-cell result | ||||
| Searched for and absent (baseline) | 144 (18) | 1.00 | .003 | |
| ND | 300 (45) | 1.38 (0.76-2.51) | .295 | |
| Present | 88 (24) | 3.01 (1.52-5.99) | .002 | |
| Stratum | ||||
| A (baseline) | 475 (75) | 1.00 | .101 | |
| B | 57 (12) | 1.80 (0.89-3.64) | .101 |
| Variable and categories . | N (N Event)* . | HR estimate (95% CI)† . | P . | Overall P‡ . |
|---|---|---|---|---|
| aGvHD2-4 | ||||
| Conditioning | ||||
| No/IS (baseline) | 343 (75) | 1.00 | .047 | |
| RIC/MAC | 202 (60) | 1.43 (1.01-2.03) | .047 | |
| Maternal T-cell result | ||||
| Searched for and absent (baseline) | 147 (37) | 1.00 | .004 | |
| ND | 311 (63) | 0.80 (0.52-1.22) | .303 | |
| Present | 87 (35) | 1.61 (0.99-2.61) | .053 | |
| Stratum | ||||
| A (baseline) | 481 (122) | 1.00 | .315 | |
| B | 64 (13) | 0.73 (0.40-1.35) | .315 | |
| cGvHD | ||||
| Donor type/TCD | ||||
| MMRD-TCD/soybean lectin (baseline) | 276 (35) | 1.00 | .019 | |
| MMRD-TCD/CD34 selection | 74 (12) | 1.16 (0.59-2.30) | .667 | |
| MMRD-other§ | 41 (10) | 3.00 (1.48-6.11) | .002 | |
| MORD | 25 (5) | 1.76 (0.69-4.52) | .239 | |
| URD | 116 (25) | 1.87 (1.10-3.18) | .021 | |
| Maternal T-cell result | ||||
| Searched for and absent (baseline) | 144 (18) | 1.00 | .003 | |
| ND | 300 (45) | 1.38 (0.76-2.51) | .295 | |
| Present | 88 (24) | 3.01 (1.52-5.99) | .002 | |
| Stratum | ||||
| A (baseline) | 475 (75) | 1.00 | .101 | |
| B | 57 (12) | 1.80 (0.89-3.64) | .101 |
For each “variable,” the categories are compared with the “baseline” reference group. The P values displayed for the individual categories of a variable help to assess the relative evidence of effect among the individual categories, relative to each other, but cannot be interpreted as common P values. The “HR” characterizes the ratio in instantaneous chance of aGvHD2-4 or cGvHD relative to the reference group. For aGvHD, other statistically significant pairwise comparisons include maternal T cells ND vs present: HR, 0.50 (95% CI, 0.33-0.75), P = .001; For cGvHD, other statistically significant pairwise comparisons include MMRD-CD34 vs MMRD-other: HR, 0.39 (95% CI, 0.16-0.94), P = .036; maternal T cells ND vs present: HR, 0.46 (95% CI, 0.27-0.78), P = .004.
ND, not determined/not done; TCD, T-cell depletion.
“N” is the number of subjects in the category of the variable; the “N event” is defined by aGvHD2-4 or cGvHD.
The “HR estimate” is for the event of aGvHD2-4 or cGvHD.
“Overall P” provides the overall significance of the variable in the model.
No TCD (n = 13) or TCD performed with anti-T12 (n = 8), monoclonal antibody not specified (n = 2), anti-CT2 (n = 1), OKT3 (n = 1), anti-Leu1 (n = 2), anti-CD6/8 (n = 1), E-rosetting (n = 3), ricin (n = 6), immunomagnetic beads not specified (n = 1), or an unknown method (n = 3).